Transitional Cell Cancer Therapeutics Market - Global Outlook and Forecast 2022-2028

January 2022 | 67 pages | ID: T414C2CD4C99EN
Market Monitor Global

Abstracts

Transitional cell carcinoma (TCC) occur in the different parts of urinary tract, which include kidney, bladder, or urethra.

This report contains market size and forecasts of Transitional Cell Cancer Therapeutics in Global, including the following market information:

Global Transitional Cell Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Transitional Cell Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Transurethral Resection Of Bladder Tumor Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Transitional Cell Cancer Therapeutics include AstraZeneca, Roche, Bristol-Myers Squibb, Pfizer, Exelixis, Eisai, Merck, Eli Lilly and Celgene. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Transitional Cell Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Transitional Cell Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Transitional Cell Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Transurethral Resection Of Bladder Tumor
• Cystectomy
• Urinary Diversion

Global Transitional Cell Cancer Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Transitional Cell Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Hospital
• Cancer Research Institutes
• Multispecialty Clinics
• Ambulatory Surgical Centers

Global Transitional Cell Cancer Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Transitional Cell Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Transitional Cell Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Transitional Cell Cancer Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• AstraZeneca
• Roche
• Bristol-Myers Squibb
• Pfizer
• Exelixis
• Eisai
• Merck
• Eli Lilly
• Celgene

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Transitional Cell Cancer Therapeutics Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Transitional Cell Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL TRANSITIONAL CELL CANCER THERAPEUTICS OVERALL MARKET SIZE

2.1 Global Transitional Cell Cancer Therapeutics Market Size: 2021 VS 2028
2.2 Global Transitional Cell Cancer Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Transitional Cell Cancer Therapeutics Players in Global Market
3.2 Top Global Transitional Cell Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Transitional Cell Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Transitional Cell Cancer Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Transitional Cell Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Transitional Cell Cancer Therapeutics Players in Global Market
  3.6.1 List of Global Tier 1 Transitional Cell Cancer Therapeutics Companies
  3.6.2 List of Global Tier 2 and Tier 3 Transitional Cell Cancer Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Transitional Cell Cancer Therapeutics Market Size Markets, 2021 & 2028
  4.1.2 Transurethral Resection Of Bladder Tumor
  4.1.3 Cystectomy
  4.1.4 Urinary Diversion
4.2 By Type - Global Transitional Cell Cancer Therapeutics Revenue & Forecasts
  4.2.1 By Type - Global Transitional Cell Cancer Therapeutics Revenue, 2017-2022
  4.2.2 By Type - Global Transitional Cell Cancer Therapeutics Revenue, 2023-2028
  4.2.3 By Type - Global Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Transitional Cell Cancer Therapeutics Market Size, 2021 & 2028
  5.1.2 Hospital
  5.1.3 Cancer Research Institutes
  5.1.4 Multispecialty Clinics
  5.1.5 Ambulatory Surgical Centers
5.2 By Application - Global Transitional Cell Cancer Therapeutics Revenue & Forecasts
  5.2.1 By Application - Global Transitional Cell Cancer Therapeutics Revenue, 2017-2022
  5.2.2 By Application - Global Transitional Cell Cancer Therapeutics Revenue, 2023-2028
  5.2.3 By Application - Global Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Transitional Cell Cancer Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Transitional Cell Cancer Therapeutics Revenue & Forecasts
  6.2.1 By Region - Global Transitional Cell Cancer Therapeutics Revenue, 2017-2022
  6.2.2 By Region - Global Transitional Cell Cancer Therapeutics Revenue, 2023-2028
  6.2.3 By Region - Global Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Transitional Cell Cancer Therapeutics Revenue, 2017-2028
  6.3.2 US Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.3.3 Canada Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.3.4 Mexico Transitional Cell Cancer Therapeutics Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Transitional Cell Cancer Therapeutics Revenue, 2017-2028
  6.4.2 Germany Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.4.3 France Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.4.4 U.K. Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.4.5 Italy Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.4.6 Russia Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.4.7 Nordic Countries Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.4.8 Benelux Transitional Cell Cancer Therapeutics Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Transitional Cell Cancer Therapeutics Revenue, 2017-2028
  6.5.2 China Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.5.3 Japan Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.5.4 South Korea Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.5.5 Southeast Asia Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.5.6 India Transitional Cell Cancer Therapeutics Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Transitional Cell Cancer Therapeutics Revenue, 2017-2028
  6.6.2 Brazil Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.6.3 Argentina Transitional Cell Cancer Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Transitional Cell Cancer Therapeutics Revenue, 2017-2028
  6.7.2 Turkey Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.7.3 Israel Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.7.4 Saudi Arabia Transitional Cell Cancer Therapeutics Market Size, 2017-2028
  6.7.5 UAE Transitional Cell Cancer Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 AstraZeneca
  7.1.1 AstraZeneca Corporate Summary
  7.1.2 AstraZeneca Business Overview
  7.1.3 AstraZeneca Transitional Cell Cancer Therapeutics Major Product Offerings
  7.1.4 AstraZeneca Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.1.5 AstraZeneca Key News
7.2 Roche
  7.2.1 Roche Corporate Summary
  7.2.2 Roche Business Overview
  7.2.3 Roche Transitional Cell Cancer Therapeutics Major Product Offerings
  7.2.4 Roche Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.2.5 Roche Key News
7.3 Bristol-Myers Squibb
  7.3.1 Bristol-Myers Squibb Corporate Summary
  7.3.2 Bristol-Myers Squibb Business Overview
  7.3.3 Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Major Product Offerings
  7.3.4 Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.3.5 Bristol-Myers Squibb Key News
7.4 Pfizer
  7.4.1 Pfizer Corporate Summary
  7.4.2 Pfizer Business Overview
  7.4.3 Pfizer Transitional Cell Cancer Therapeutics Major Product Offerings
  7.4.4 Pfizer Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.4.5 Pfizer Key News
7.5 Exelixis
  7.5.1 Exelixis Corporate Summary
  7.5.2 Exelixis Business Overview
  7.5.3 Exelixis Transitional Cell Cancer Therapeutics Major Product Offerings
  7.5.4 Exelixis Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.5.5 Exelixis Key News
7.6 Eisai
  7.6.1 Eisai Corporate Summary
  7.6.2 Eisai Business Overview
  7.6.3 Eisai Transitional Cell Cancer Therapeutics Major Product Offerings
  7.6.4 Eisai Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.6.5 Eisai Key News
7.7 Merck
  7.7.1 Merck Corporate Summary
  7.7.2 Merck Business Overview
  7.7.3 Merck Transitional Cell Cancer Therapeutics Major Product Offerings
  7.7.4 Merck Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.7.5 Merck Key News
7.8 Eli Lilly
  7.8.1 Eli Lilly Corporate Summary
  7.8.2 Eli Lilly Business Overview
  7.8.3 Eli Lilly Transitional Cell Cancer Therapeutics Major Product Offerings
  7.8.4 Eli Lilly Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.8.5 Eli Lilly Key News
7.9 Celgene
  7.9.1 Celgene Corporate Summary
  7.9.2 Celgene Business Overview
  7.9.3 Celgene Transitional Cell Cancer Therapeutics Major Product Offerings
  7.9.4 Celgene Transitional Cell Cancer Therapeutics Revenue in Global Market (2017-2022)
  7.9.5 Celgene Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Transitional Cell Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Transitional Cell Cancer Therapeutics Market Drivers in Global Market
Table 3. Transitional Cell Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Transitional Cell Cancer Therapeutics in Global Market
Table 5. Top Transitional Cell Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Transitional Cell Cancer Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Transitional Cell Cancer Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Transitional Cell Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Transitional Cell Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Transitional Cell Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Transitional Cell Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Transitional Cell Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Transitional Cell Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Transitional Cell Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Transitional Cell Cancer Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Transitional Cell Cancer Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. AstraZeneca Corporate Summary
Table 31. AstraZeneca Transitional Cell Cancer Therapeutics Product Offerings
Table 32. AstraZeneca Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Roche Corporate Summary
Table 34. Roche Transitional Cell Cancer Therapeutics Product Offerings
Table 35. Roche Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. Bristol-Myers Squibb Corporate Summary
Table 37. Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Product Offerings
Table 38. Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Corporate Summary
Table 40. Pfizer Transitional Cell Cancer Therapeutics Product Offerings
Table 41. Pfizer Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. Exelixis Corporate Summary
Table 43. Exelixis Transitional Cell Cancer Therapeutics Product Offerings
Table 44. Exelixis Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Eisai Corporate Summary
Table 46. Eisai Transitional Cell Cancer Therapeutics Product Offerings
Table 47. Eisai Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Merck Corporate Summary
Table 49. Merck Transitional Cell Cancer Therapeutics Product Offerings
Table 50. Merck Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly Corporate Summary
Table 52. Eli Lilly Transitional Cell Cancer Therapeutics Product Offerings
Table 53. Eli Lilly Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Celgene Corporate Summary
Table 55. Celgene Transitional Cell Cancer Therapeutics Product Offerings
Table 56. Celgene Transitional Cell Cancer Therapeutics Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Transitional Cell Cancer Therapeutics Segment by Type in 2021
Figure 2. Transitional Cell Cancer Therapeutics Segment by Application in 2021
Figure 3. Global Transitional Cell Cancer Therapeutics Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Transitional Cell Cancer Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Transitional Cell Cancer Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Transitional Cell Cancer Therapeutics Revenue in 2021
Figure 8. By Type - Global Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Transitional Cell Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Transitional Cell Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. AstraZeneca Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Roche Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Bristol-Myers Squibb Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Exelixis Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Eisai Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Merck Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Celgene Transitional Cell Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)